Clinical Trial Update: Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment [Phase 1]

View source ↗

Summary

Phase I study evaluating safety, tolerability and pharmacokinetics of an investigational M1 muscarinic receptor agonist for cognitive impairment; the trial in h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• M1 muscarinic receptor agonist (investigational)

Snippet

Sponsor: Nxera Pharma UK Limited | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED